
Supplemental Figure 1. HERO Registry and HERO-HCQ Trial Timeline



Supplemental Table 1. Participating PCORnet HERO-HCQ Trial Sites

AdventHealth Orlando

Allina Health

Baylor Scott and White Memorial Hospital

Children's Hospital Colorado

Clinical Trials Center of Middle Tennessee

Columbia University Medical Center

Duke University Hospital

Hospital for Special Surgery

Johns Hopkins Hospital

Marshfield Clinic

Mayo Clinic

Michigan Medicine

New York Presbyterian/Weill Cornell Medical Center

Northwestern University

Ochsner Clinic Foundation

Rush University Medical Center

Seattle Children's Hospital

Tampa General Hospital

Temple University Hospital

The Ohio State University Wexner Medical Center

University Medical Center- New Orleans

University of Florida Health

University of Florida Health Central Florida

University of Florida Jacksonville Shands Medical Center

University of Iowa

University of Kansas Medical Center

University of Miami Miller School of Medicine

University of Missouri - Columbia

University of Nebraska Medical Center

University of North Carolina at Chapel Hill

University of Pittsburgh School of Medicine

University of Texas Southwestern Medical Center Dallas

Vanderbilt University Medical Center

Wake Forest Baptist Medical Center

Supplemental Table 2. Comparison of Confidence Interval (CI) Estimates for the Primary Analysis

| CI Method | 95% CI (% scale) |
|------------------------|------------------|
| Miettinen-Nurminen | -4.60, 0.87 |
| Chang-Zhang | -4.61, 0.90 |
| Agresti-Caffo | -4.55, 0.88 |
| Hauck-Anderson | -4.61, 0.94 |
| Miettinen-Nurminem-Mee | -4.60, 0.87 |
| Newcombe | -4.59, 0.88 |
| Newcombe (corrected) | -4.69, 0.99 |
| Wald (corrected) | -4.68, 1.01 |

Note: the point estimate is -1.84% favoring HCQ vs. placebo at Day 30. The 2-sided Fisher's exact p-value is 0.20.

Supplemental Table 3. Comparison of COVID PREP and HERO-HCQ studies

| | COVID PREP (NCT04328467) | HERO-HCQ (NCT04334148) |
|-------------------------------------|---|---|
| Randomization ratio | 2:2:1:1 | 1:1 |
| | (the placebo arms were pooled) | |
| HCQ dosage | Loading dose of 400 mg (two 200-mg tablets) twice separated by 6-8 hours followed by (i) 400 mg (two 200-mg tablets) once weekly for 12 weeks or (ii) 400 mg (two 200-mg tablets) twice weekly for 12 weeks | 600-mg loading dose of study drug twice on the first day, followed by 400 mg daily for 29 days |
| Maximum follow-up | 3 months | Treatment period for 30 days with follow-up at Day 60 |
| Planned sample size | ~3,150 HCW | 15,000 HCW |
| | (1050 per arm) | (7500 per arm) |
| Final sample size | 1483 | 1359 |
| (% of planned) | (47.2%) | (9.1%) |
| HCQ primary endpoint event rate | 58/989 (5.9%) | 41/683 (6.0%) |
| Placebo primary endpoint event rate | 39/494 (7.9%) | 53/676 (7.8%) |

Mantel—Haenszel Common Odds Ratio = **0.74** (**95%** CI **0.55** to **1.00**), **p= 0.046**. Breslow-Day Test of Homogeneity p-value= 0.92.